Skip to main content

bit.bio’s new Huntington’s disease human cell model, for in vitro research and drug discovery


via The Scientist RSS https://ift.tt/EAWYKNx bit.bio’s new ioGlutamatergic Neurons HTT50CAG/WT provide a human, cell-based, in vitro model of Huntington’s Disease (HD) that accurately reflects the disease genotype. Offering industry-leading consistency and scalability, this first product from the new ioDisease Model portfolio has been developed to support key applications within drug discovery including target identification and high-throughput screening. https://ift.tt/aZhUgyR June 10, 2022 at 12:16AM
Labels:

Comments

Post a Comment

Popular posts from this blog

Enhancing Cell Morphology-Based Analysis

via The Scientist RSS https://ift.tt/RkiFxGZ Learn how the latest AI-driven technology uses morphology to comprehensively analyze and sort cell populations. https://ift.tt/0hfk7tr August 03, 2023 at 10:19PM
Post a Comment
Read more

Accessible Lateral Flow Assays: Test to Treat, Test to Protect

via The Scientist RSS https://ift.tt/7aXpZQb From development to implementation, Rosanna Peeling discusses the importance of rapid tests for public health. https://ift.tt/xEQe8l9 October 18, 2023 at 08:30PM
Post a Comment
Read more

Engineered Bacteria Make Tumors More T Cell-Friendly

via The Scientist RSS https://ift.tt/Ku7FXvh Microbes designed to produce specific immunomodulatory metabolites could give immunotherapy a boost. https://ift.tt/xy2vXPZ April 08, 2022 at 08:41PM
Post a Comment
Read more